Opus Net Receivables from 2010 to 2026
| IRD Stock | 3.60 0.21 6.19% |
Net Receivables | First Reported 2010-12-31 | Previous Quarter 6.6 M | Current Value 7 M | Quarterly Volatility 2.6 M |
Check Opus Genetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Opus Genetics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.4 K, Interest Expense of 0.0 or Selling General Administrative of 22 M, as well as many indicators such as Price To Sales Ratio of 3.16, Dividend Yield of 0.0 or PTB Ratio of 4.47. Opus financial statements analysis is a perfect complement when working with Opus Genetics Valuation or Volatility modules.
Opus | Net Receivables | Build AI portfolio with Opus Stock |
Analyzing Opus Genetics's Net Receivables over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Receivables has evolved provides context for assessing Opus Genetics's current valuation and future prospects.
Latest Opus Genetics' Net Receivables Growth Pattern
Below is the plot of the Net Receivables of Opus Genetics over the last few years. It is Opus Genetics' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Opus Genetics' overall financial position and show how it may be relating to other accounts over time.
| Net Receivables | 10 Years Trend |
|
Net Receivables |
| Timeline |
Opus Net Receivables Regression Statistics
| Arithmetic Mean | 1,636,029 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 159.96 | |
| Mean Deviation | 2,162,629 | |
| Median | 125,000 | |
| Standard Deviation | 2,616,923 | |
| Sample Variance | 6.8T | |
| Range | 7M | |
| R-Value | 0.77 | |
| Mean Square Error | 2.9T | |
| R-Squared | 0.60 | |
| Significance | 0.0003 | |
| Slope | 400,843 | |
| Total Sum of Squares | 109.6T |
Opus Net Receivables History
About Opus Genetics Financial Statements
Opus Genetics stakeholders use historical fundamental indicators, such as Opus Genetics' Net Receivables, to determine how well the company is positioned to perform in the future. Although Opus Genetics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Opus Genetics' assets and liabilities are reflected in the revenues and expenses on Opus Genetics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Opus Genetics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Receivables | 6.6 M | 7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Opus Genetics is a strong investment it is important to analyze Opus Genetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Opus Genetics' future performance. For an informed investment choice regarding Opus Stock, refer to the following important reports:Check out the analysis of Opus Genetics Correlation against competitors. For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Will Pharmaceuticals sector continue expanding? Could Opus diversify its offerings? Factors like these will boost the valuation of Opus Genetics. Market participants price Opus higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Opus Genetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.86) | Revenue Per Share | Quarterly Revenue Growth (0.20) | Return On Assets | Return On Equity |
Understanding Opus Genetics requires distinguishing between market price and book value, where the latter reflects Opus's accounting equity. The concept of intrinsic value - what Opus Genetics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Opus Genetics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Opus Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Opus Genetics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.